Murat Torgutalp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Murat Torgutalp has a total of 287 co-authors. Here are the top co-authors by number of shared publications:
- Fabian Proft
Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin , Berlin
24 shared publications - Denis Poddubnyy
Division of Rheumatology, Department of Medicine, University of Toronto and Schroeder Arthritis Institute, University Health Network, Toronto, Canada
22 shared publications - Judith Rademacher
Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité Universitätsmedizin Berlin, Berlin, Germany
18 shared publications - Müçteba Enes Yayla
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara 06230, Turkey
17 shared publications - Mikhail Protopopov
Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité Universitätsmedizin Berlin, Berlin, Germany
16 shared publications - Valeria Rios Rodriguez
Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin
16 shared publications
Latest Publications
- 21 September 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (10) , e107-e108
Response to correspondence on ‘Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study’ by Luan et al
- 21 September 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (10) , e107-e108
Response to correspondence on ‘Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study’ by Luan et al
- Open Access
- 9 August 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (7) , 1508-1517
Proteomic Tear Fluid Analysis in Acute Anterior Uveitis Reveals Distinct Characteristics During Active Inflammation
Uveitis is a potentially vision-threatening intraocular inflammation of the uvea, predominantly observed in individuals aged 20 to 60 years. Anterior uveitis (AU) — characterized by inflammation of...
- 9 August 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (7) , 1508-1517
Open AccessProteomic Tear Fluid Analysis in Acute Anterior Uveitis Reveals Distinct Characteristics During Active Inflammation
Uveitis is a potentially vision-threatening intraocular inflammation of the uvea, predominantly observed in individuals aged 20 to 60 years. Anterior uveitis (AU) — characterized by inflammation of...
- Open Access
- 1 August 2026
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 18
Clinical and imaging characteristics of patients with axial psoriatic arthritis: Baseline findings from the GESPIC-axial-PsA cohort
Background: Axial disease is a domain of psoriatic arthritis (PsA), referred to as axial-PsA. Despite recent advances and increasing recognition, axial-PsA remains poorly defined; validated classification criteria and longitudinal cohorts are lacking. Objectives: We aimed to characterise axial-PsA and delineate phenotypes in an imaging-confirmed cohort. Design: GESPIC-axPsA, a dedicated arm of the German Spondyloarthritis Inception Cohort (GESPIC), is a prospective, monocentric, study including patients with psoriasis and clinically diagnosed axial-PsA confirmed by imaging. Baseline assessments included clinical phenotyping, laboratory testing, biosample-collection, radiographs of the axial skeleton, and MRI of the whole spine and sacroiliac joints (SIJs). Methods: The analysis was primarily descriptive, characterizing baseline clinical and imaging features of patients with imaging-confirmed axial-PsA; categorical and continuous variables were summarized using appropriate measures based on their distribution, and subgroup comparisons were performed using chi-square or Fisher’s exact tests for categorical variables and Mann–Whitney U tests for continuous variables after assessing normality. Results: We enrolled 107 axial-PsA patients (55% female; mean age 44.8 years); 78.5% had active psoriasis, 78.6% had inflammatory back pain (IBP), and 48.6% were HLA-B27 positive. Radiographic sacroiliitis was present in 45.7%. On MRI, active/structural SIJ lesions were seen in 53.3%/73.3%; spinal active/structural lesions in 60.0%/53.3%. Both Classification criteria for axSpA (ASAS) and PsA (CASPAR) were simultaneously fulfilled in 60.7%. We identified 20 patients (18.7%) with spine-only involvement—spinal MRI lesions without SIJ lesions on radiography or MRI. Compared with the remainder, the spine-only group was older, more often female, less frequently HLA-B27–positive, and had back pain less consistent with IBP (all p<0.05). Conclusions: In our imaging-confirmed axial-PsA cohort using standardized whole-spine and SIJ MRI, we observed marked phenotypic heterogeneity. Approximately one fifth had isolated spinal involvement; this subgroup differed by age, sex, HLA-B27, and IBP features, with imaging distributions distinct from axSpA—supporting the need for disease-specific classification criteria.
- 1 August 2026
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 18
Open AccessClinical and imaging characteristics of patients with axial psoriatic arthritis: Baseline findings from the GESPIC-axial-PsA cohort
Background: Axial disease is a domain of psoriatic arthritis (PsA), referred to as axial-PsA. Despite recent advances and increasing recognition, axial-PsA remains poorly defined; validated classification criteria and longitudinal cohorts are lacking. Objectives: We aimed to characterise axial-PsA and delineate phenotypes in an imaging-confirmed cohort. Design: GESPIC-axPsA, a dedicated arm of the German Spondyloarthritis Inception Cohort (GESPIC), is a prospective, monocentric, study including patients with psoriasis and clinically diagnosed axial-PsA confirmed by imaging. Baseline assessments included clinical phenotyping, laboratory testing, biosample-collection, radiographs of the axial skeleton, and MRI of the whole spine and sacroiliac joints (SIJs). Methods: The analysis was primarily descriptive, characterizing baseline clinical and imaging features of patients with imaging-confirmed axial-PsA; categorical and continuous variables were summarized using appropriate measures based on their distribution, and subgroup comparisons were performed using chi-square or Fisher’s exact tests for categorical variables and Mann–Whitney U tests for continuous variables after assessing normality. Results: We enrolled 107 axial-PsA patients (55% female; mean age 44.8 years); 78.5% had active psoriasis, 78.6% had inflammatory back pain (IBP), and 48.6% were HLA-B27 positive. Radiographic sacroiliitis was present in 45.7%. On MRI, active/structural SIJ lesions were seen in 53.3%/73.3%; spinal active/structural lesions in 60.0%/53.3%. Both Classification criteria for axSpA (ASAS) and PsA (CASPAR) were simultaneously fulfilled in 60.7%. We identified 20 patients (18.7%) with spine-only involvement—spinal MRI lesions without SIJ lesions on radiography or MRI. Compared with the remainder, the spine-only group was older, more often female, less frequently HLA-B27–positive, and had back pain less consistent with IBP (all p<0.05). Conclusions: In our imaging-confirmed axial-PsA cohort using standardized whole-spine and SIJ MRI, we observed marked phenotypic heterogeneity. Approximately one fifth had isolated spinal involvement; this subgroup differed by age, sex, HLA-B27, and IBP features, with imaging distributions distinct from axSpA—supporting the need for disease-specific classification criteria.
- Open Access
Impact of vitamin D levels on disease activity, function and health over 2 years in radiographic axial spondyloarthritis: data from GErman SPondyloarthritis Inception Cohort (GESPIC)
Objectives: To investigate the impact of vitamin D on disease activity, function and health in patients with radiographic axial spondyloarthritis (r-axSpA) undergoing biological disease-modifying antirheumatic drug (bDMARD) therapy. Methods: Patients with r-axSpA and active disease at baseline initiating a bDMARD were included in this analysis. Vitamin D (25-hydroxyvitamin D) was measured at baseline and every 6 months until year 2; deficiency was defined as <20 ng/mL. The outcomes were AxSpA Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Patient Global Assessment (PGA), Bath Ankylosing Spondylitis Functional Index (BASFI), Assessment of SpondyloArthritis international Society Health Index (ASAS-HI) and C reactive protein (CRP). Longitudinal associations were evaluated using generalised estimating equations, with sensitivity analyses accounting for time-varying confounders. Results: We analysed 122 patients (mean age 36.6 (10.3) years; 66.4% male), of whom 53.3% had vitamin D deficiency at baseline. In longitudinal models, normal vitamin D levels were associated with lower ASDAS (β per 1 ng/mL increase: −0.010; 95% CI −0.017 to −0.003), BASDAI (β: −0.021; 95% CI −0.036 to −0.006), PGA (β: −0.021; 95% CI −0.039 to −0.003) and BASFI (β: −0.015; 95% CI −0.032 to 0.001). Effect estimates of ASDAS, BASDAI, BASFI, CRP (and their corresponding categorical outcomes) were attenuated in sensitivity analyses but remained directionally consistent. Positive associations with PGA and ASAS-HI were also observed though the estimates were not consistent through all models. Conclusions: Normal vitamin D levels were modestly associated with lower disease activity in r-axSpA treated with bDMARDs. Monitoring and optimising vitamin D status may support better disease control.
Open AccessImpact of vitamin D levels on disease activity, function and health over 2 years in radiographic axial spondyloarthritis: data from GErman SPondyloarthritis Inception Cohort (GESPIC)
Objectives: To investigate the impact of vitamin D on disease activity, function and health in patients with radiographic axial spondyloarthritis (r-axSpA) undergoing biological disease-modifying antirheumatic drug (bDMARD) therapy. Methods: Patients with r-axSpA and active disease at baseline initiating a bDMARD were included in this analysis. Vitamin D (25-hydroxyvitamin D) was measured at baseline and every 6 months until year 2; deficiency was defined as <20 ng/mL. The outcomes were AxSpA Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Patient Global Assessment (PGA), Bath Ankylosing Spondylitis Functional Index (BASFI), Assessment of SpondyloArthritis international Society Health Index (ASAS-HI) and C reactive protein (CRP). Longitudinal associations were evaluated using generalised estimating equations, with sensitivity analyses accounting for time-varying confounders. Results: We analysed 122 patients (mean age 36.6 (10.3) years; 66.4% male), of whom 53.3% had vitamin D deficiency at baseline. In longitudinal models, normal vitamin D levels were associated with lower ASDAS (β per 1 ng/mL increase: −0.010; 95% CI −0.017 to −0.003), BASDAI (β: −0.021; 95% CI −0.036 to −0.006), PGA (β: −0.021; 95% CI −0.039 to −0.003) and BASFI (β: −0.015; 95% CI −0.032 to 0.001). Effect estimates of ASDAS, BASDAI, BASFI, CRP (and their corresponding categorical outcomes) were attenuated in sensitivity analyses but remained directionally consistent. Positive associations with PGA and ASAS-HI were also observed though the estimates were not consistent through all models. Conclusions: Normal vitamin D levels were modestly associated with lower disease activity in r-axSpA treated with bDMARDs. Monitoring and optimising vitamin D status may support better disease control.
- Top Cited PapersOpen Access
- 26 March 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (6) , 1092-1109
Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study
- 26 March 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (6) , 1092-1109
Top Cited PapersOpen AccessFrequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study
- Open Access
- 26 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 582-591
The Impact of Nonsteroidal Anti‐Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From an Inception Cohort
Objective: This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA]). Methods: Leveraging data from the German Spondyloarthritis Inception Cohort (GESPIC), we conducted analyses on 252 patients with axSpA (139 with nr‐axSpA and 113 with r‐axSpA), who had minimum two sets of spinal radiographs. The outcome was progression in modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in two‐year intervals. We fitted sequential conditional mean models by using generalized estimating equations and adjusting for longitudinal repeated measures of exposure and time‐dependent confounders. We report β‐coefficients with 95% confidence intervals (CIs) for outcomes reflecting the progression in mSASSS per 10‐point increase in NSAID intake score. Results: At baseline, 201 (80.0%) patients were under NSAID treatment, with 46 (18%) taking COX2i and 156 (62%) taking ns‐NSAIDs, and mean total NSAID intake score was 38.3 ± 35.5. A 10‐point increase in NSAID intake score was associated with retardation of radiographic progression (β = −0.052, 95% CI: −0.097 to −0.007), with this effect being most pronounced in patients with r‐axSpA (β = −0.077, 95% CI: −0.152 to −0.003). COX2i showed a slightly lower point estimate (although not statistically significant) in progression compared to ns‐NSAIDs among all patients with axSpA (β = −0.061 and −0.045, respectively). Conclusion: Our findings suggest a beneficial effect of higher NSAID intake, particularly COX2i, on slowing radiographic progression in axSpA. These findings may help inform therapeutic strategies, particularly in r‐axSpA, although further research is needed for nr‐axSpA. image
- 26 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 582-591
Open AccessThe Impact of Nonsteroidal Anti‐Inflammatory Drugs on Radiographic Spinal Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From an Inception Cohort
Objective: This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA]). Methods: Leveraging data from the German Spondyloarthritis Inception Cohort (GESPIC), we conducted analyses on 252 patients with axSpA (139 with nr‐axSpA and 113 with r‐axSpA), who had minimum two sets of spinal radiographs. The outcome was progression in modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in two‐year intervals. We fitted sequential conditional mean models by using generalized estimating equations and adjusting for longitudinal repeated measures of exposure and time‐dependent confounders. We report β‐coefficients with 95% confidence intervals (CIs) for outcomes reflecting the progression in mSASSS per 10‐point increase in NSAID intake score. Results: At baseline, 201 (80.0%) patients were under NSAID treatment, with 46 (18%) taking COX2i and 156 (62%) taking ns‐NSAIDs, and mean total NSAID intake score was 38.3 ± 35.5. A 10‐point increase in NSAID intake score was associated with retardation of radiographic progression (β = −0.052, 95% CI: −0.097 to −0.007), with this effect being most pronounced in patients with r‐axSpA (β = −0.077, 95% CI: −0.152 to −0.003). COX2i showed a slightly lower point estimate (although not statistically significant) in progression compared to ns‐NSAIDs among all patients with axSpA (β = −0.061 and −0.045, respectively). Conclusion: Our findings suggest a beneficial effect of higher NSAID intake, particularly COX2i, on slowing radiographic progression in axSpA. These findings may help inform therapeutic strategies, particularly in r‐axSpA, although further research is needed for nr‐axSpA. image
- Open Access
Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT
Objective: To investigate complement system activation and complement protein levels in relation to radiographic progression in axial spondyloarthritis (axSpA) within a longitudinal randomised controlled trial (RCT) of radiographic axSpA patients initiating tumour necrosis factor inhibitor (TNFi) therapy. Methods: Serum samples from 96 patients with active radiographic axSpA in the multicentre RCT CONSUL were analysed by immunoassays for complement activation, that is, C3dg and complement proteins (MBL, CL-L1, M-, H- and L-ficolin; MASP-1,–2 and −3; and MAp44) before and after 108 weeks of TNF inhibitor therapy with golimumab. Results: Baseline serum levels of total complement activation, that is, C3dg and lectin pathway activating protease MASP-1 were elevated in patients with new bone formation (new syndesmophytes and/or growth of existing syndesmophytes) after 2 years of follow-up, whereas baseline MASP-3 levels were decreased. Assessed by univariate logistic regression, baseline levels of MASP-1, MASP-3 and C3dg were associated with the development of new bone formation and remained significant in a corresponding multivariate logistic regression analysis. At follow-up, serum levels of C3dg and complement lectin pathway initiator L-ficolin were elevated in patients with new bone formation, and C3dg remained significant in a corresponding multivariate logistic regression analysis. Conclusions: Complement activation marker C3dg, MASP-1 and MASP-3 levels before TNFi therapy predicted new bone formation after 2 years of follow-up among axSpA patients with a high risk of radiographic progression. Furthermore, levels of L-ficolin and C3dg at follow-up were elevated in axSpA patients with new bone formation. Our findings support an association between activation of the complement system and radiographic spinal progression in patients with axSpA.
Open AccessComplement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT
Objective: To investigate complement system activation and complement protein levels in relation to radiographic progression in axial spondyloarthritis (axSpA) within a longitudinal randomised controlled trial (RCT) of radiographic axSpA patients initiating tumour necrosis factor inhibitor (TNFi) therapy. Methods: Serum samples from 96 patients with active radiographic axSpA in the multicentre RCT CONSUL were analysed by immunoassays for complement activation, that is, C3dg and complement proteins (MBL, CL-L1, M-, H- and L-ficolin; MASP-1,–2 and −3; and MAp44) before and after 108 weeks of TNF inhibitor therapy with golimumab. Results: Baseline serum levels of total complement activation, that is, C3dg and lectin pathway activating protease MASP-1 were elevated in patients with new bone formation (new syndesmophytes and/or growth of existing syndesmophytes) after 2 years of follow-up, whereas baseline MASP-3 levels were decreased. Assessed by univariate logistic regression, baseline levels of MASP-1, MASP-3 and C3dg were associated with the development of new bone formation and remained significant in a corresponding multivariate logistic regression analysis. At follow-up, serum levels of C3dg and complement lectin pathway initiator L-ficolin were elevated in patients with new bone formation, and C3dg remained significant in a corresponding multivariate logistic regression analysis. Conclusions: Complement activation marker C3dg, MASP-1 and MASP-3 levels before TNFi therapy predicted new bone formation after 2 years of follow-up among axSpA patients with a high risk of radiographic progression. Furthermore, levels of L-ficolin and C3dg at follow-up were elevated in axSpA patients with new bone formation. Our findings support an association between activation of the complement system and radiographic spinal progression in patients with axSpA.
- 5 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 40-41
Update on the Axial Involvement in Psoriatic Arthritis (AXIS) Project
Psoriatic arthritis (PsA) is an inflammatory disease associated with psoriasis, often affecting both peripheral and axial skeletal structures. Axial symptoms affect a significant portion of individuals with PsA. The Axial Involvement in Psoriatic Arthritis (AXIS) study, a multinational, multicenter cross-sectional study conducted under the umbrella of the Group for Research on Psoriasis and Psoriatic Arthritis (GRAPPA) and Assessment of SpondyloArthritis international Society (ASAS), aimed to establish a unified definition and classification criteria for axial involvement in PsA. The study enrolled 409 patients from 41 centers across 19 countries. Comprehensive clinical and imaging assessments were conducted for each patient including radiographs and magnetic resonance imaging of the sacroiliac joints and spine. Imaging data were reviewed by both local investigators and a central imaging committee. Final judgment on the presence or absence of axial involvement was made by investigators following evaluation of all data by the investigators and the central expert imaging team. Axial involvement was assessed to be present in 112/409 patients (27.4%). Data analysis is ongoing and the full study results are expected shortly. This update was presented at the GRAPPA 2024 annual meeting.
- 5 August 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (Suppl 3) , 40-41
Update on the Axial Involvement in Psoriatic Arthritis (AXIS) Project
Psoriatic arthritis (PsA) is an inflammatory disease associated with psoriasis, often affecting both peripheral and axial skeletal structures. Axial symptoms affect a significant portion of individuals with PsA. The Axial Involvement in Psoriatic Arthritis (AXIS) study, a multinational, multicenter cross-sectional study conducted under the umbrella of the Group for Research on Psoriasis and Psoriatic Arthritis (GRAPPA) and Assessment of SpondyloArthritis international Society (ASAS), aimed to establish a unified definition and classification criteria for axial involvement in PsA. The study enrolled 409 patients from 41 centers across 19 countries. Comprehensive clinical and imaging assessments were conducted for each patient including radiographs and magnetic resonance imaging of the sacroiliac joints and spine. Imaging data were reviewed by both local investigators and a central imaging committee. Final judgment on the presence or absence of axial involvement was made by investigators following evaluation of all data by the investigators and the central expert imaging team. Axial involvement was assessed to be present in 112/409 patients (27.4%). Data analysis is ongoing and the full study results are expected shortly. This update was presented at the GRAPPA 2024 annual meeting.
- Open Access
- 27 July 2025
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 17
Similarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis
Spondyloarthritis is a group of chronic inflammatory diseases that includes axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA primarily affects the axial skeleton, manifesting with hallmark features such as inflammatory back pain and a strong association with human leukocyte antigen-B27. On the other hand, axial involvement in PsA (axial PsA) poses unique challenges in the diagnosis, classification, and management. These challenges stem from a limited understanding of this condition and an absence of a specific definition for its diagnosis. Although shared genetic and environmental contributors are observed, the presence of differences suggests the possibility that axial PsA may, in fact, represent a distinct clinical entity rather than axSpA. The prevailing classification criteria, such as ClASsification criteria for Psoriatic ARthritis for PsA and the Assessment of SpondyloArthritis International Society criteria for axSpA, are insufficient in capturing the full scope of axial PsA. Moreover, treatment paradigms for axial PsA are primarily extrapolated from axSpA due to the lack of targeted trials in this specific population. Biologic disease-modifying anti-rheumatic drugs, encompassing tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, and Janus kinase inhibitors, have demonstrated efficacy in axSpA and PsA. However, IL-23 inhibitors have not shown efficacy in axSpA, and currently, no results from randomized controlled trials in axial PsA are available. While axial PsA exhibits features that overlap with axSpA, emerging evidence underscores its distinct pathophysiology and clinical characteristics, highlighting the need for standardized definitions and tailored therapeutic approaches to optimize outcomes. Ongoing studies evaluating therapeutic efficacy and molecular characterization hold promises to enhance understanding and management of axial PsA, thus paving the way for personalized treatment strategies. This review aims to provide an overview of the similarities and differences between axial PsA and axSpA and seeks to disentangle the intersections between these two diseases.
- 27 July 2025
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 17
Open AccessSimilarities and differences: disentangling the intersection between axial psoriatic arthritis and axial spondyloarthritis
Spondyloarthritis is a group of chronic inflammatory diseases that includes axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA primarily affects the axial skeleton, manifesting with hallmark features such as inflammatory back pain and a strong association with human leukocyte antigen-B27. On the other hand, axial involvement in PsA (axial PsA) poses unique challenges in the diagnosis, classification, and management. These challenges stem from a limited understanding of this condition and an absence of a specific definition for its diagnosis. Although shared genetic and environmental contributors are observed, the presence of differences suggests the possibility that axial PsA may, in fact, represent a distinct clinical entity rather than axSpA. The prevailing classification criteria, such as ClASsification criteria for Psoriatic ARthritis for PsA and the Assessment of SpondyloArthritis International Society criteria for axSpA, are insufficient in capturing the full scope of axial PsA. Moreover, treatment paradigms for axial PsA are primarily extrapolated from axSpA due to the lack of targeted trials in this specific population. Biologic disease-modifying anti-rheumatic drugs, encompassing tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, and Janus kinase inhibitors, have demonstrated efficacy in axSpA and PsA. However, IL-23 inhibitors have not shown efficacy in axSpA, and currently, no results from randomized controlled trials in axial PsA are available. While axial PsA exhibits features that overlap with axSpA, emerging evidence underscores its distinct pathophysiology and clinical characteristics, highlighting the need for standardized definitions and tailored therapeutic approaches to optimize outcomes. Ongoing studies evaluating therapeutic efficacy and molecular characterization hold promises to enhance understanding and management of axial PsA, thus paving the way for personalized treatment strategies. This review aims to provide an overview of the similarities and differences between axial PsA and axSpA and seeks to disentangle the intersections between these two diseases.
- Open Access
Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort
Objective: Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms as a key element. The aim of this study was to analyse the longitudinal association of early axSpA with achieving low disease activity or inactive disease. Methods: Using 10-year longitudinal data from the German Spondyloarthritis Inception Cohort (GESPIC), a generalised estimating equations model was fitted to estimate the effect of early axSpA on disease activity, as measured by the Axial Spondyloarthritis Disease Activity Score (ASDAS). The model adjusted for confounders identified through a directed acyclic graph and accounted for repeated measurements within patients. Additional analyses were conducted, including stratification by radiographic status (non-radiographic—nr or radiographic—r). Results: Of 525 patients (277 nr-axSpA, 248 r-axSpA) included in GESPIC, 161 (30%) fulfilled the ASAS early axSpA consensus definition (115 nr-axSpA and 46 r-axSpA) at baseline. Over the 10-year follow-up period, patients with early axSpA consistently achieved ASDAS states of inactive disease or low disease activity at a higher rate than those with non-early axSpA, rising from 41% versus 30% at baseline to 57% versus 44% at year 10. The total effect of early axSpA on ASDAS was −0.42 (95% CI: −0.57 to –0.26). Stratification by r-axSpA/nr-axSpA showed a total effect of −0.50 (95% CI: −0.81 to –0.19) for r-axSpA and −0.28 (95% CI: −0.46 to –0.10) for nr-axSpA. Conclusion: Fulfilment of the ASAS early axSpA definition at inclusion was associated with lower disease activity over 10 years.
Open AccessLongitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort
Objective: Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms as a key element. The aim of this study was to analyse the longitudinal association of early axSpA with achieving low disease activity or inactive disease. Methods: Using 10-year longitudinal data from the German Spondyloarthritis Inception Cohort (GESPIC), a generalised estimating equations model was fitted to estimate the effect of early axSpA on disease activity, as measured by the Axial Spondyloarthritis Disease Activity Score (ASDAS). The model adjusted for confounders identified through a directed acyclic graph and accounted for repeated measurements within patients. Additional analyses were conducted, including stratification by radiographic status (non-radiographic—nr or radiographic—r). Results: Of 525 patients (277 nr-axSpA, 248 r-axSpA) included in GESPIC, 161 (30%) fulfilled the ASAS early axSpA consensus definition (115 nr-axSpA and 46 r-axSpA) at baseline. Over the 10-year follow-up period, patients with early axSpA consistently achieved ASDAS states of inactive disease or low disease activity at a higher rate than those with non-early axSpA, rising from 41% versus 30% at baseline to 57% versus 44% at year 10. The total effect of early axSpA on ASDAS was −0.42 (95% CI: −0.57 to –0.26). Stratification by r-axSpA/nr-axSpA showed a total effect of −0.50 (95% CI: −0.81 to –0.19) for r-axSpA and −0.28 (95% CI: −0.46 to –0.10) for nr-axSpA. Conclusion: Fulfilment of the ASAS early axSpA definition at inclusion was associated with lower disease activity over 10 years.